Supplements · Metabolic & Cardiometabolic

coenzyme Q10 improves chronic heart failure

In plain terms: Can CoQ10 help people with heart failure?

Leans support Supplements

RefutedContestedStrong support

consensus score 0.36

It leans helpful as an add-on for reduced-ejection-fraction heart failure, but rests heavily on a single pivotal trial still awaiting replication.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Human trials (RCT / n-of-1)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

4 support 0 contradict 0 tested null 6 mixed · 10 sources, 3 independent groups

What the evidence shows

CoQ10 as an adjunct in HFrEF leans supportive: the pivotal Q-SYMBIO RCT reported improved MACE/mortality (European subgroup consistent), and independent smaller RCTs (e.g. Belardinelli) found better myocardial contractility and cardiocirculatory/endothelial function.

Cochrane has no ruling yet see how our grade compares ▾

Cochrane review 2021 · Moderate Not directly comparable

all-cause mortality & HF hospitalisation); very low (LVEF, exercise capacity)

“The included studies provide moderate-quality evidence that coenzyme Q10 probably reduces all-cause mortality and hospitalisation for heart failure. There is low-quality evidence of inconclusive results as to whether coenzyme Q10 has an effect on the risk of myocardial infarction, or stroke. Because of very low-quality evidence, it is very uncertain whether coenzyme Q10 has an effect on either left ventricular ejection fraction or exercise capacity. There is low-quality evidence that coenzyme Q10 may increase the risk of adverse effects, or have little to no difference. There is currently no convincing evidence to support or refute the use of coenzyme Q10 for heart failure. Future trials are needed to confirm our findings.”

Not directly comparable: their review asks a different question or reports an outcome we do not grade, so it neither corroborates nor contradicts this claim.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (10)

Source	Grade	Stance	Quality	Finding
Mortensen et al. 2019 · Cardiol J	RCT	supports	low	Q-SYMBIO European subgroup (RCT double-blind, CoQ10 100 mg t.i.d. + standard therapy): treatment effect consistent with the main trial's benefit on HF outcomes.
Soongswang et al. 2005 · Pediatr Cardiol	observational	mixed	low	Open-label pediatric dilated-cardiomyopathy study: CoQ10 improved NYHA/CT-ratio but not significant after multiple-comparison correction.
Belardinelli et al. 2006 · Biofactors	RCT	supports	moderate	RCT: CoQ10 + exercise training improved cardiocirculatory efficiency and endothelial function in CHF.
Belardinelli et al. 2005 · Biofactors	RCT	supports	moderate	RCT: CoQ10 improved contractility of dysfunctional myocardium in CHF (same group as Belardinelli 2006).
Claxton et al. 2022 · Health Technol Assess	meta-analysis	mixed	moderate	NIHR HTA systematic review + economic evaluation of CoQ10 in HFrEF: may improve symptoms/progression but evidence and cost-effectiveness uncertain (cautious).
Arun AJ et al 2025 · study_type: observational	observational	mixed	moderate	Narrative review stating Q-SYMBIO showed CoQ10 significantly reduced cardiovascular and all-cause mortality in chronic HF and improved functional capacity/EF with minimal side effects.
Bodea O et al 2025 · study_type: RCT	RCT	supports	moderate	RCT, n=120 HF patients, CoQ10 120mg/day vs placebo x6 months: GLS improved (-11.7% to -14.9%, p<0.001), NT-proBNP fell (815.6 vs 1378.5 pg/mL, p=0.012), 6MWT improved (349.3 vs 267.0m, p=0.008); LVEF change not significant (38.9%->40.6%, p=
Chua et al. 2025 · Complement Ther Med	meta-analysis	mixed	moderate	Umbrella review of integrative medicine for chronic HF: CoQ10 among adjuncts with some positive SR/MA evidence, but overall certainty variable.
Kumble J et al 2026 · study_type: observational	observational	mixed	moderate	Narrative review citing Q-SYMBIO as demonstrating improved functional capacity, EF, and reduced MACE in HFrEF. No new independent data; reiterates the single-trial finding.
Rosenfeldt et al. 2003 · Biofactors	meta-analysis	mixed	moderate	SR + pilot RCT + MA of 9 HF trials: non-significant trends toward higher EF and lower mortality; too few patients for firm conclusion.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.